Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Archean Chemical Industries Limited (ACI.NS)
Chennai, IN
Archean Chemical Industries Limited operates as a manufacturer and global distributor of specialized chemicals extracted from marine sources, serving markets both within India and worldwide. Its product portfolio prominently features bromine, an essential chemical with widespread applications across sectors such as pharmaceuticals, agrochemicals, water purification, flame retardancy, various industrial additives, the oil and gas industry, and advanced energy storage solutions. The company also supplies industrial salt, which serves as a crucial raw material for the chemical industry in the production of substances like sodium carbonate, caustic soda, hydrochloric acid, chlorine, bleaching agents, chlorates, sodium sulphate, and metallic sodium. Additionally, Archean provides sulphate of potash, valued for its dual utility as an agricultural fertilizer and for certain medical applications. Established in 2003, the company maintains its headquarters in Chennai, India.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.85% | -6.32% | -3.87% | +3.07% | -7.12% | +5.26% | -3.54% | +11.12% | +28.00% | +28.00% | +28.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Chemicals: +4.0%+3.9% Q1'26: -12.9% (vs Q1'25)
-
EPS growth Chemicals: +11.7%-34.1% Q1'26: -74.3% (vs Q1'25)
-
FCF margin FCF growth · Chemicals: +41.7%+2.0% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Chemicals: +7.1%+13.5% ★ Q1'26: +6.9% (vs Q1'25)
-
ROIC Chemicals: +3.4%+4.5% ★ Q1'26: +2.8% (vs Q1'25)
-
Share dilution Chemicals: +0.0%0.0% Q1'26: -3.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals: 0.55×1.95× Q1'26: 2.67× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 6 Rev. Ana. 5 EPS Ana. |
Mar 2027 6 Rev. Ana. 6 EPS Ana. |
Mar 2028 6 Rev. Ana. 6 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
14.40B
est: 14.45B (-0.4%)
|
13.30B
est: 12.00B (+10.9%)
|
10.41B
est: 10.51B (-0.9%)
|
11.18B
10.85B – 11.69B
+6.4% YoY
|
15.78B
14.51B – 16.52B
+41.2% YoY
|
20.24B
18.24B – 22.27B
+28.3% YoY
|
| EBITDA |
6.77B
est: 5.63B (+20.3%)
|
5.06B
est: 4.67B (+8.2%)
|
3.11B
est: 4.09B (-24.0%)
|
4.35B
4.23B – 4.56B
+6.4% YoY
|
6.15B
5.65B – 6.44B
+41.2% YoY
|
7.89B
7.11B – 8.68B
+28.3% YoY
|
| EBIT |
6.06B
est: 4.73B (+28.0%)
|
4.34B
est: 3.93B (+10.5%)
|
2.32B
est: 3.44B (-32.6%)
|
3.66B
3.55B – 3.83B
+6.4% YoY
|
5.17B
4.75B – 5.41B
+41.2% YoY
|
6.63B
5.97B – 7.29B
+28.3% YoY
|
| Net Income |
3.83B
est: 4.13B (-7.4%)
|
3.19B
est: 2.70B (+18.1%)
|
1.62B
est: 2.25B (-27.9%)
|
1.52B
1.30B – 1.78B
-32.4% YoY
|
3.21B
2.95B – 3.59B
+111.3% YoY
|
4.46B
4.20B – 4.79B
+38.9% YoY
|
| SGA |
5.37B
est: 5.90B (-8.9%)
|
5.29B
est: 4.90B (+8.0%)
|
4.55B
est: 4.29B (+6.1%)
|
4.56B
4.43B – 4.77B
+6.4% YoY
|
6.44B
5.92B – 6.74B
+41.2% YoY
|
8.26B
7.44B – 9.09B
+28.3% YoY
|
| EPS |
34.66
est: 33.43 (+3.7%)
|
25.90
est: 21.91 (+18.2%)
|
13.13
est: 18.36 (-28.5%)
|
12.30
10.50 – 14.40
-33.0% YoY
|
25.84
23.85 – 29.02
+110.1% YoY
|
36.46
33.99 – 38.73
+41.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.03% | 197.1K | 0.65% |
| 2 | WisdomTree India Earnings Fund EPI | 0.01% | 146.5K | 0.84% |
| 3 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 36.8K | 0.28% |
| 4 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 18.6K | 0.29% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ranjit Pendurthi | MD & Executive Director | 203M | male |
| Vijayaraghavan | Company Secretary & Compliance Officer | 3M | male |
| Rajeev Kumar | Head of Strategy | — | male |
| Bhupathi K. | Vice President of Operations & Unit head | — | male |
| Vijay Vyas | Head of Sales & Marketing | — | male |
| Ramamurthy Natarajan | Chief Financial Officer | — | male |
| Nagayanallur Ramachandran Kannan | Executive Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ACI.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
